0
Abstract: Slide Presentations |

EFFICACY AND SAFETY OF 23-VALENT PNEUMOCOCCAL POLYSACCHARIDE VACCINE IN PREVENTION OF LOWER RESPIRATORY TRACT INFECTIONS IN THE CHINESE ELDERLY: A PROSPECTIVE CONCURRENT CONTROLLED TRIAL FREE TO VIEW

Bi R. Dong, PhD*; Yin Xu, MD; Yan L. Zhang, MD; Ji R. Yue, MD
Author and Funding Information

West China Hospital, Chengdu, Peoples Rep of China


Chest


Chest. 2005;128(4_MeetingAbstracts):148S. doi:10.1378/chest.128.4_MeetingAbstracts.148S
Text Size: A A A
Published online

Abstract

PURPOSE:  The aime of the study is to assess the efficacy, safety and cost-effectiveness of this vaccine in prevention of lower respiratory tract infections (LRTIs) in Chinese elderly.

METHODS:  600 subjects of 60 years old were divided into experimental and control groups( 300 each group). Data on name, sex, age, smoking and exercise habits, monthly per capita income, living conditions, influenza vaccine status, immunoenhancers use and diseases –particularly LRTIs –3 months prior to the study were collected for baseline comparison. During a 1-year follow-up period, both groups were observed for incidence and severity of LRTIs, hospitalization rates, length of hospital stay, antibiotic use and direct medical costs.

RESULTS:  Overall, the vaccine reduced LRTIs, antibiotic use and hospitalization by 69.7%, 72.6% and 65.9%, respectively. Stratified analysis showed vaccine reduced the incidence and severity of LRTIs as well as rates of antibiotic use and hospitalization in subjects with COPD or CHD. In subjects who had diabetes mellitus, hypertension or were inoculated with the influenza vaccine, the vaccine was a protective factor in LRTIs and rate of antibiotic use, but reductions in hospitalization rates were not significant. The vaccine did not reduce the incidence and severity of LRTIs or the rates of antibiotic use and hospitalization in subjects classified as healthy. Side effects were noted in 91 subjects, including 80 with local reactions at the injection site, 9 with systemic reactions, and two with both local and systemic reactions. All adverse reactions were mild and resolved within 1 to 3 days by local stupe or rest.The benefit-cost ratio was 2.06, with a net benefit of ¥66,471.65.

CONCLUSION:  23-valent pneumococcal polysaccharide vaccination among the elderly community is effective in reducing the incidence and severity of LRTIs. It also decreases antibiotic use the frequency and duration of hospitalization.

CLINICAL IMPLICATIONS:  The protective efficacy of this vaccine is particularly significant in patients with COPD and CHD and it is cost-effective and safe.

DISCLOSURE:  Bi Dong, None.

Monday, October 31, 2005

2:30 PM - 4:00 PM


Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543